Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SOUTH SAN FRANCISCO, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
-
Study did not meet primary endpoint of fibrosis improvement by >1 stage with no worsening of NASH versus placeboStatistical significance achieved versus placebo on certain secondary endpoints,...
-
SOUTH SAN FRANCISCO, Calif., May 23, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) will host a conference call and live webcast on Monday, May 24, 2021 at 8:30 a.m. ET (5:30...
-
Expect to report topline data from Phase 2b ALPINE 2/3 clinical trial of aldafermin in patients with NASH with F2 and F3 liver fibrosis in the second quarterContinued enrollment in Phase 2 CATALINA...
-
SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
-
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Financial Results
•Significant progress made across liver and metabolic diseases, retinal diseases and cancer during fourth quarter 2020: •Presented first-in-human results from Phase 1 clinical trial of NGM621 in...
-
--Placebo-controlled study to evaluate potential of NGM120, a novel inhibitor of GDF15/GFRAL pathway, to treat cancer and cancer-related cachexia-- --Cachexia, a wasting syndrome, is a common...
-
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
-
--Humanized IgG1 monoclonal antibody engineered to potently inhibit complement C3, with the potential for extended every eight-week dosing-- --CATALINA Phase 2 study of NGM621 in patients with...
-
NGM advances its vision to build the next iconic biologics company, fueled by its in-house discovery engineSignificant progress made across all three therapeutic area portfolios in 2020Phase 2b or...